Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Opus Genetics, Inc.IRD · Entity 5892 | SVP of Corp. Dev. | March 13, 2025 | March 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Opus Genetics, Inc.
Report date March 13, 2025 · Filed March 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 185,446 |
Reported balance
After 2025-03-13 transaction · row 1
1 source rowRow 1 · 2025-03-13 · Grant · Acquired 29,500 · Balance 185,446 F1: Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of March 13, 2025, subject to the Reporting Person's continuing service. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2035-03-12 | Direct | 29,500 |
Reported balance
After 2025-03-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-03-13 · Grant · Acquired 29,500 · Balance 29,500 F2: The option will vest with respect to 25% on March 13, 2026, with the remaining shares vesting quarterly in 12 equal installments thereafter at the end of each quarter, subject to the Reporting Person's continuing service. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of March 13, 2025, subject to the Reporting Person's continuing service.
F2: The option will vest with respect to 25% on March 13, 2026, with the remaining shares vesting quarterly in 12 equal installments thereafter at the end of each quarter, subject to the Reporting Person's continuing service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2025 Filed Mar 18, 2025 00:49 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 29,500 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000905148-25-000937 · form4.xml · derivative · entry 2 Hoffmann Bernhard · CIK 0001830354 · SVP of Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,500 Underlying: Common Stock · 29,500 shares Expires 2035-03-12 F2 · derivative.exercise_date: The option will vest with respect to 25% on March 13, 2026, with the remaining shares vesting quarterly in 12 equal installments thereafter at the end of each quarter, subject to the Reporting Person's continuing service. Read SEC document |
| March 13, 2025 Filed Mar 18, 2025 00:49 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 29,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000937 · form4.xml · nonDerivative · entry 1 Hoffmann Bernhard · CIK 0001830354 · SVP of Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,446 F1 · shares: Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of March 13, 2025, subject to the Reporting Person's continuing service. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:35 UTC | Opus Genetics, Inc. IRD · Entity 5892 | Tax withholdingCommon Stock | 6,751 | $1.14 | $7,696.14 |
DisclosureSEC source: 0000905148-25-000401 · form4.xml · nonDerivative · entry 1 Hoffmann Bernhard · CIK 0001830354 · SVP of Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,946 Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 23:01 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0001140361-24-003192 · form4.xml · derivative · entry 2 Hoffmann Bernhard · CIK 0001830354 · SVP of Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-01-17 F2 · derivative.exercise_date: The option will vest with respect to 7,500 shares on January 18, 2025, with the balance vesting quarterly in twelve equal installments thereafter at the end of each quarter. Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 23:01 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-003192 · form4.xml · nonDerivative · entry 1 Hoffmann Bernhard · CIK 0001830354 · SVP of Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,697 F1 · shares: Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of January 18, 2024. Read SEC document |
| January 10, 2024 Filed Jan 12, 2024 21:17 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | Tax withholdingCommon Stock | 4,031 | $3.27 | $13,161.22 |
DisclosureSEC source: 0001140361-24-002126 · form4.xml · nonDerivative · entry 1 Hoffmann Bernhard · CIK 0001830354 · SVP of Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,697 Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 22:33 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 69,912 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001140361-23-001513 · form4.xml · derivative · entry 2 Hoffmann Bernhard · CIK 0001830354 · SVP of Corp. Dev. & Ops & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,912 Underlying: Common Stock · 69,912 shares Expires 2033-01-09 F2 · derivative.exercise_date: The option will vest with respect to 17,478 shares on January 10, 2024, with the balance vesting quarterly in twelve equal installments thereafter. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 22:33 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 46,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-001513 · form4.xml · nonDerivative · entry 1 Hoffmann Bernhard · CIK 0001830354 · SVP of Corp. Dev. & Ops & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,728 F1 · shares: Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of January 10, 2023. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:29 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 42,500 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001140361-22-003497 · form4.xml · derivative · entry 1 Hoffmann Bernhard · CIK 0001830354 · VP of Corp. Dev. & Ops & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2032-01-27 F1 · derivative.exercise_date: The option will vest with respect to 10,625 shares on January 28, 2023, and then with respect to 885 shares on the last day of each month from February 2023 through December 2025 and with respect to 900 shares at the end of January 2026. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 21:57 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001140361-20-025524 · form4.xml · derivative · entry 1 Hoffmann Bernhard · CIK 0001830354 · VP of Corp. Dev. & Ops & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-11-11 F1 · derivative.exercise_date: 416 shares vest each month-end from November 2020 through September 2024. The balance vests in October 2024. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 22:57 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 4,226 | Not disclosed Strike: $1.65 | Not disclosed |
DisclosureSEC source: 0001596771-20-000110 · primary_doc.xml · derivative · entry 4 Hoffmann Bernhard · CIK 0001830354 · VP of Corp. Dev. and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,226 Underlying: Common Stock · 4,226 shares Expires 2020-06-30 F1 · price: The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc. F4 · derivative.exercise_date: 1,373 shares vested on June 30, 2020, and the remaining shares vest in equal monthly installments from July 2020 through December 2021, subject to continued service. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 22:57 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 30,110 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0001596771-20-000110 · primary_doc.xml · derivative · entry 3 Hoffmann Bernhard · CIK 0001830354 · VP of Corp. Dev. and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,110 Underlying: Common Stock · 30,110 shares Expires 2029-12-27 F1 · price: The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc. F3 · derivative.exercise_date: 3,486 shares vested on December 31, 2019, and the remaining shares vest in equal monthly installments from January 2020 through December 2021, subject to continued service. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 22:57 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 42,867 | Not disclosed Strike: $0.90 | Not disclosed |
DisclosureSEC source: 0001596771-20-000110 · primary_doc.xml · derivative · entry 2 Hoffmann Bernhard · CIK 0001830354 · VP of Corp. Dev. and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,867 Underlying: Common Stock · 42,867 shares Expires 2028-10-01 F1 · price: The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 22:57 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 100,120 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001596771-20-000110 · primary_doc.xml · nonDerivative · entry 1 Hoffmann Bernhard · CIK 0001830354 · VP of Corp. Dev. and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,120 F1 · price: The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.